Recruiting

ECGenius® & PFAnalyzer

Sponsor:

CathVision ApS

Code:

NCT07275151

Conditions

Atrial Fibrillation

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Pulmonary vein isolation ablation

Study Details

Brief summary:

The study is a prospective, exploratory observational study with the ECGenius® System and the PFAnalyzer software module in PFA cases using the FaraPulse PFA system. The cohort will be patients with paroxysmal or persistent atrial fibrillation (AF) who undergo PVI using this system.

Conditions

Atrial Fibrillation

Study ID

NCT07275151

Start date

Jul 22, 2026

Status verified date

Jul, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Oct 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Eligible subjects will meet all of the following inclusion criteria:

1. Subjects undergoing first time pulmonary vein isolation indicated by investigator for the treatment of atrial fibrillation.
2. Male or non-pregnant female aged ≥21 years.
3. Able and willing to provide written informed consent prior to any clinical investigation related procedure.
4. Subjects in sinus rhythm at the time of the PFA application.

Exclusion Criteria:

Eligible subjects will not meet any of the following exclusion criteria:

1. Pregnant or nursing subjects.
2. Current participation in another investigational drug or device study that interferes with this study.
3. Subjects who, in the opinion of the investigator, are not candidates for this study.
4. Patients who have had a prior ablation procedure.
5. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
6. Life expectancy is less than 12 months, in the opinion of the investigator.
7. Subjects who, in the opinion of the investigator, are considered part of any vulnerable population.
8. Subjects unlikely to be in sinus rhythm at the time of the procedure or unlikely to remain in sinus rhythm after cardioversion

Study Design

Enrollment

40 participants

Anticipated

Interventions and Outcome Measures

Interventions

Pulmonary vein isolation ablation

Electrical isolation of the pulmonary veins to treat atrial fibrillation

Primary outcome measure

  • Pulmonary vein isolation [ Time Frame: intra-procedural ]

Central Contacts and Locations

Central contacts

Locations

The Valley Hospital

Recruiting

Paramus, New Jersey, United States, 07652

Contacts

Principal Investigator:

Dan Musat, MD

More Information

Sponsor

CathVision ApS

Last update posted

Jul 23, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by CathVision ApS on 2026-07-23.